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Abstract
Background: Body Mass Index (BMI) as a marker of obesity is an established risk factor for chronic kidney disease (CKD) and
cardiovascular disease (CVD). However, BMI can overestimate obesity. Anthropomorphic measurements that include central
fat deposition are emerging as a more important risk factor. We studied BMI, waist circumference (WC), waist-to-height ratio
(WHtR), waist-to-hip ratio (WHR) and conicity index (CI) in a cohort of patients with CKD stage 3 and compared the
associations with other known risk factors for CKD progression and CVD.
Methods: 1740 patients with CKD stage 3 were recruited from primary care for the Renal Risk in Derby study. Each
participant underwent clinical assessment, including anthropomorphic measurements and pulse wave velocity (PWV), as
well as urine and serum biochemistry tests.
Results: The mean age of the cohort was 72.969 years with 60% females. The mean eGFR was 52.5610.4 ml/min/1.73 m
2
and 16.9% of the cohort had diabetes. With the cohort divided into normal and increased risk of morbidity and mortality
using each anthropomorphic measurement, those measurements that included increased central fat distribution were
significantly associated with more risk factors for CKD progression and CVD than increased BMI. Univariable analysis
demonstrated central fat distribution was correlated with more risk factors than BMI. Subgroup analyses using recognised
BMI cut-offs to define obesity and quartiles of WHR and CI demonstrated that increasing central fat distribution was
significantly associated with more CKD and CVD risk factors than increasing BMI.
Conclusion: Anthropomorphic measurements that include a measure of central fat deposition are related to more key risk
factors in CKD stage 3 patients than BMI. Central fat deposition may be of greater importance as a risk factor in CKD than
BMI and reliance on BMI alone may therefore underestimate the associated risk.
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Introduction
Overweight and obesity, defined by body mass index (BMI;
kg/m
2), are associated with increased risk of hypertension [1],
diabetes [2], malignancy [3] and mortality [4]. In addition, an
association between obesity and chronic kidney disease (CKD) has
been identified over the past 10 years. Several population-based,
observational studies showed obesity, defined by BMI, as an
independent risk factor in the development of CKD [5,6] and end
stage kidney disease (ESKD) [7]. In other studies overweight,
obesity and increased central fat distribution (as defined by waist-
to-hip ratio, WHR) have been associated with reduced estimated
glomerular filtration rate (eGFR) and microalbuminuria [8]. In
African Americans with hypertensive nephrosclerosis, BMI was
shown to be independently associated with urinary protein and
albumin excretion [9]. Recently, increasing waist circumference
(WC) categories were associated with an increased mortality risk in
a population with CKD stages1-4 [10]. The effect of obesity in
haemodialysis patients is more controversial with a number of
studies reporting a reduction in the relative risk of mortality with
increasing BMI [11] but the inclusion of a measure of central fat
deposition associates with an increased mortality risk [12,13].
Current UK CKD management guidelines recommend routine
BMI measurement but do not recommend assessment of central
fat distribution [14].
There is mounting evidence to suggest that BMI may not be the
ideal measure of obesity, especially when used to assess disease
risk. BMI is indiscriminate; including fat mass and muscle mass in
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mass, but normal fat mass, could have a raised BMI and be
wrongly defined as overweight or obese. BMI does not account for
the differing distributions of body fat between individuals or
populations [15]. Increased abdominal fat deposition is associated
with insulin resistance [15], is a stronger risk factor for morbidity
and mortality than peripheral fat deposition [16] and varies greatly
within a narrow BMI range [15].
A number of other methods for assessing obesity related
morbidity that include measures of abdominal fat deposition have
been proposed for assessing obesity related health risk. WC and
WHR are the most commonly used methods and are associated
with obesity-related morbidity and mortality [17]. Waist-to-height
ratio (WHtR) correlates well with CT assessment of intra-
abdominal fat [18] and one study found it to be more strongly
associated with cardiovascular disease (CVD) risk than WHR, WC
or BMI [19]. Conicity Index (CI) is a measure that includes
weight, height and WC; it demonstrates good association with
WHR [20] and at increasing levels has been associated with
increased mortality risk in a haemodialysis population [13].
To examine which method for assessing obesity-related health
risk may be the most appropriate in patients with CKD we studied
the relationship between a number of different anthropomorphic
measurements and established risk factors for CKD progression
and CVD in a community-based cohort with CKD stage 3.
Methods
Subjects and recruitment
A detailed description of the methods has been published
previously and is summarised here with emphasis on the
anthropomorphic variables studied [21,22]. The Renal Risk In
Derby (RRID) study was conducted from a single Nephrology
Department. Subjects were directly recruited from community
medical care practices. Study visits were conducted at participat-
ing community medical centres by the researchers. Eligible
participants were adult, met the KDOQI criteria for CKD stage
3 (eGFR 30–59 mL/min/1.73 m
2 on 2 or more occasions at least
3 months apart prior to recruitment), able to give informed
consent and attend their GP surgery for assessments by the
researchers. People who had previously had a solid organ
transplant or were terminally ill (expected survival ,1 year) were
excluded.
Data collection
We combined screening and baseline visits due to the logistical
challenges associated with conducting study visits in multiple
primary care centres and the large proportion of elderly
participants. Each participant was sent a medical and dietary
questionnaire and 3 urine specimen bottles. They were requested
not to eat cooked meat for at least 12 hours prior to the assessment
[23].
At the assessment anthropomorphic measurements were taken
(height, weight, WC and hip circumference, HC). Blood specimens
were taken and with urine specimens were submitted for
biochemical analysis. Blood pressure (BP) and pulse wave velocity
(PWV) were also measured. Diabetes was defined by having a
previous clinical diagnosis in line with WHO criteria [24].
Anthropomorphic Measurements
Weight and height measurements were taken at assessment. WC
was measured as per WHO guidelines; at the mid-point between
the lower border of the rib cage and the iliac crest. HC was
measured at the widest point of the hips and the maximal
protrusion of the gluteal muscles [17].
BMI was computed as weight (in kilograms) divided by the
square of the height (in metres). WHR ratio was computed as the
ratio of WC to HC. WHtR was computed as the ratio of WC to
height. CI was calculated using the following formula:
CI~WC= 0:109HWeight=Height

[20] Overweight was defined as a BMI $25–29.9 kg/m
2 and
obesity defined as a BMI $30 kg/m
2. Central fat distribution was
defined as a WHR of $0.9 for men or $0.85 for women; a WC of
.94 cm for Europid males, .90 cm for Asian/Chinese/Japanese
males and .80 cm for all females; a WHtR of .0.5 for males and
females [17].
Blood pressure
BP was measured after a minimum of five minutes rest in the
sitting position, using an oscillometric device, recommended by
the British Hypertension Society. The same device was used for all
readings. BP was calculated as the mean of three readings that
differed by ,10% [25].
Pulse wave velocity
PWV was measured as a marker of arterial stiffness, a critical
determinant of cardiovascular outcomes in CKD [26,27].
Measurements were performed using a Vicorder
TM device
(Skidmore Medical Ltd, Bristol, UK) between carotid and femoral
arteries.
Albuminuria
Albuminuria was assessed by measuring the urine albumin to
creatinine ratio (UACR) on three consecutive early morning urine
specimens collected prior to the clinic visit and stored in a
refrigerator [23].
Estimation of glomerular filtration rate
Biochemical assessments were performed by autoanalyser in a
single laboratory. The creatinine assay has been standardised
against an isotope dilution mass spectrometry (IDMS) method.
The modified 4-variable MDRD equation was used to estimate
GFR.
Ethics
The study was approved by the Nottingham Research Ethics
Committee 1 and abides by the principles of the Declaration of
Helsinki. All participants provided written consent. The study was
included on the National Institute for Health Research (NIHR)
Clinical Research Portfolio (NIHR Study ID:6632) and was
independently audited by QED Clinical Services in November
2009.
Statistical Analysis
Variables are reported as the mean and standard deviation (SD)
if normally distributed or the median and inter-quartile range
(IQR) if not. A t-test was used to compare groups where variables
were normally distributed and a Mann-Whitney test used if not.
Univariable linear regression analysis was used to evaluate
independent associations between anthropomorphic variables
(independent variables) and risk factors for CKD progression or
CVD (eGFR, Log UACR, PWV and serum uric acid used as
dependent variables). SPSS version 16.0 was used for analysis and
p,0.05 was considered statistically significant.
Anthropomorphic Measurements in CKD Stage 3
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Overall 22% of the approximately 8,280 potential participants
invited agreed to be included in the study. A total of 1822 subjects
were enrolled between July 2008 and March 2010, 81 were
excluded because they did not meet the inclusion criteria despite
being on a CKD register at their GP practice; 1 further patient
was excluded due to incomplete anthropomorphic data. Thus a
total of 1740 participants were included in this analysis.
Baseline data are shown in Table 1. The mean weight was
78.2615.5 kg and mean BMI 2965.1 kg/m
2. Forty two percent
of the cohort were classified overweight (BMI $25–29.9 kg/m
2)
and 37% classified obese (BMI $30 kg/m
2). Seventy three percent
of the cohort had increased central fat distribution as defined by
WHR ($0.9 for men or $0.85 for women) [17].
The cohort was divided into overweight or obese and non-
overweight defined by BMI, or normal risk and increased risk of
metabolic complications, defined by WC, WHtR and WHR. CI
was excluded from this analysis as currently no agreed cut-off for
increased risk exists in the literature. Increased BMI and WC were
associated with only a minority of risk factors for CKD progression
and CVD but WHtR and WHR were each associated with
multiple factors (Table 2).
Univariable analyses were performed between continuous
anthropomorphic measurements and risk factors associated with
CKD progression and CVD. Increasing BMI, WC and WHtR
were significantly correlated with a minority of risk factors whereas
WHR and CI were significantly correlated with multiple risk
factors (Table 3).
The cohort was then divided into subgroups using recognised
BMI cutoffs (#24.9; 25–29.9; 30–39.9; $40), WHR quartiles and
CI quartiles. Increasing BMI was associated with a significant
increase in serum uric acid concentration whereas PWV decreased
with increasing BMI (Table 4). In contrast WHR and CI were
comparably associated with a significant change in multiple risk
factors (Tables 5 and 6).
The analysis was repeated with diabetic subjects excluded and
all associations observed in the whole cohort were reproduced
(data not shown). Further subgroup analyses were performed with
the cohort divided into age ,75 yrs; age $75years and CKD
stage 3a (eGFR: 60-46 mL/min/1.73 m
2) ; CKD stage 3b (eGFR:
45-30 mL/min/1.73 m
2).
Patients aged $75 yrs had a significantly higher mean uric acid
(p,0.001), PWV(p,0.001), SBP(p,0.001), WHR (p=0.007) and
CI(p,0.001) and a significantly lower mean eGFR(p,0.001) and
BMI (p,0.001) compared with those aged ,75 yrs. Comparisons
between normal and raised anthropomorphic measures, univari-
able analyses and comparisons between BMI subgroups and
WHR, CI quartiles were similar in both age groups to those of the
full cohort. The CKD3a results were similar to those of the full
cohort; unfortunately the CKD3b group was statistically under-
powered (n=410) and produced no significant results (data not
shown).
Discussion
This study shows that anthropomorphic measurements that
include central fat distribution are associated with more estab-
lished risk factors for CKD progression and CVD than BMI.
On the basis of age, eGFR and albuminuria the RRID study
cohort is broadly representative of patients with CKD followed up
in primary care, in the UK [28]. A greater percentage of the
cohort was overweight and obese (defined by BMI) than would be
expected from general UK population data (79% with CKD stage
3 compared to 66% of men and 57% of women in the general
population) and this trend continued when comparing proportions
of obesity alone (37% with CKD stage 3 compared with 22% men
and 24% of women from the general population) [29].
When examining the relationship between anthropomorphic
cut-offs for increased risk and other risk factors, a raised WHR was
significantly associated with more risk factors than the other
measures. The association with increasing age is supported by
previous findings of increasing all-cause mortality in a cohort aged
$70 years with increasing WHR; a similar relationship was not
found with BMI [30]. This highlights another limitation of BMI
which tends to decrease in the elderly (as demonstrated with the
association of decreasing mean age as BMI groups increased in our
cohort – Table 4) as the decrease in BMI is a reflection of the loss
of skeletal muscle mass experienced with aging as opposed to loss
of fat mass [30].
A raised WHR was also significantly associated with a decreased
eGFR, increased UACR and serum uric acid. The association
with decreased eGFR agrees with previous findings reporting a
relationship between increasing WHR and diminishing glomerular
filtration [8] as well as incident CKD and mortality [31]. This
relationship with eGFR is important given that decreasing eGFR
is associated with an increased risk of CV and all-cause mortality
[32]. The association of increased WHR with the increased
UACR is significant given that UACR has been found to be a
stronger risk factor for progression of CKD than low baseline
eGFR [33] and increased UACR increases the risk of CV and all
cause mortality [32]. Mean serum uric acid levels, identified in
previous studies as an independent CV risk marker in subjects with
[34] and without CKD [35,36,37], were also increased in the
raised WHR group.
Univariable analyses demonstrated WHR and CI correlating
with more risk factors than any other anthropomorphic measure.
WC and WHtR were associated with similar, but fewer, risk
factors to WHR and CI and all include measures of central fat
deposition. Unexpectedly BMI was negatively correlated with
PWV, a surrogate marker of arterial stiffness. Increased arterial
Table 1. Baseline Data.
Cohort (n=1740)
Age (years) 72.969
Female 1052(60.4)
SBP(mmHg) 134618
Diabetes 294(16.9)
eGFR (ml/min/1.73 m
2) 52.5610.4
UACR (mg/mmol) 0.33[0–1.5]
Uric Acid (mmol/L) 384.2691.2
PWV (m/sec) 9.962.0
Weight (Kg) 78.2615.5
BMI (kg/m
2) 2965.1
WC (cm) 97.6612.8
WHR 0.9160.09
WHtR 0.660.07
CI 1.360.09
Data are mean6SD, median [IQR] or number (%).
SBP=systolic blood pressure; eGFR=estimated glomerular filtration rate;
UACR=urine albumin to creatinine ratio; PWV=pulsewave velocity; BMI=body
mass index; WC=waist circumference; WHR=waist-to-hip ratio; WHtR=waist-
to-height ratio; CI=conicity index.
doi:10.1371/journal.pone.0034699.t001
Anthropomorphic Measurements in CKD Stage 3
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34699stiffness is emerging as a major risk factor for CV disease [38,39]
and has been identified as an independent risk factor for CV death
in the general population [40] as well as in subjects with CKD
[26,41]. This finding is therefore contrary to what we would
expect from the literature [26,42,43]. Our observation may be
explained by the fact that BMI decreased with increasing age in
our study population and age is a major determinant of increasing
PWV [44]. In contrast, WHR did not decrease with increasing
age, suggesting that it is a better marker of obesity in an elderly
population.
Dividing the cohort into subgroups using recognised BMI cut-
offs, WHR quartiles and CI quartiles demonstrated a significant
difference between the subgroups in more risk factors for CKD
progression and CV disease with WHR and CI quartiles than with
BMI subgroups.
Our data suggest an advantage to having a measurement of
central fat distribution when assessing risk of CKD progression
and CVD in a cohort with CKD stage 3 and we offer the following
explanation for this. A number of factors have been implicated in
the pathogenesis of obesity-related kidney disease, such as:
hyperfiltration, excess fatty acid accumulation in tissue (lipotoxi-
city), increased insulin resistance and alterations in circulating
adipokine levels [45]. Adipose tissue is a large endocrine organ
secreting a number of different adipokines. Obese subjects have a
different adipokine profile compared to lean subjects with obese
subjects having increased levels of pro-inflammatory adipokines
(PIAs). Obesity is therefore associated with low-grade inflamma-
tion [46] that has been proposed as a causative link between
obesity and its complications [47]. The mechanisms that provoke
increased secretion of PIAs await further elucidation. Hypoxic
conditions in animals and in-vitro in white adipose tissue are
associated with increased PIA secretion [46] and peri-operative
measurement of oxygen levels in abdominal adipose tissue showed
a decreased oxygen tension in obese subjects, when compared to
non-obese [48]. Therefore, increased tissue hypoxia observed with
increasing central fat distribution may be a driving factor
underlying obesity-related morbidity. It is only by measuring
central fat distribution that this effect can be taken into account.
Interestingly, as all anthropomorphic measures of obesity
increased, serum uric acid levels also rose significantly within the
cohort. An increased serum uric is associated with increased CV
risk [49]. It is raised in CKD and the metabolic syndrome [49].
Whether it is actually a risk factor for CKD progression and the
metabolic syndrome is yet to be proven, and the subject of ongoing
research [49].
Strengths of this study include confirmation of CKD stage 3 by
two eGFR values (often lacking in epidemiological studies), serum
creatinine measurements performed after a 12 hour meat fast and
samples assayed in a single laboratory using an assay standardised
to an IDMS method as well as urine chemistry repeated on three
consecutive early morning specimens to minimise the effect of
daily variation in low levels of albuminuria. We have therefore
established a robust baseline dataset that will allow detailed
analysis of the predictive value of differing anthropomorphic
measurements as potential risk factors when outcome data become
available.
Several limitations of this study need to be acknowledged.
Despite rigorous application of the entry criteria, some subjects
had an eGFR$60 mL/min/1.73 m
2 at their first clinical visit.
Follow up will yield important data on the natural history and
associated risks of this subgroup. For ethical reasons we were
obliged to rely on eligible patients volunteering to participate and
this strategy may have introduced an element of bias, since those
more concerned about their health would be more likely to
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representative of patients followed up in Primary Care with CKD
stage 3, though it may not be representative of all such
populations. The cohort includes only a minority of subjects of
African or Asian origin as the population in Derbyshire is
predominantly Caucasian. Several studies have reported a high
prevalence of CKD and obesity in African and Asian populations
associated with a higher risk of CKD progression and our
observations may therefore not be directly applicable to these
ethnic groups.
Conclusion
Anthropomorphic measurements that include a measure of
central fat deposition are related to more key risk factors in CKD
stage 3 patients than BMI. Central fat deposition may be of greater
importance as a risk factor in CKD than BMI and reliance on
Table 3. Univariable analysis between continuous anthropomorphic measures and established risk factors for CKD progression or
cardiovascular events.
BMI WC WHtR WHR CI
Dependent Variable Beta Std.Error Beta Std.Error Beta Std.Error Beta Std.Error Beta Std.Error
eGFR (mL/min/1.73 m
2)20.06 0.05 20.09* 0.02 213.70* 3.31 220.37* 2.77 216.89* 2.63
SBP(mmHg) 0.03 0.09 0.06 0.03 5.42 5.87 10.52# 4.96 9.61# 4.69
Log UACR 0.004 0.007 0.017* 0.003 2.015* 0.495 3.860* 0.411 3.100* 0.391
Uric acid (mmol/L) 3.48* 0.42 2.20* 0.16 295.74* 28.37 317.20* 23.58 257.92* 22.63
PWV (m/sec) 20.053* 0.01 0.001 0.004 20.776 0.652 2.776* 0.544 2.962* 0.513
*p,0.001;
#p,0.05.
All Coefficients reported are unstandardised.
eGFR=estimated glomerular filtration rate; SBP=systolic blood pressure; UACR=urine albumin to creatinine ratio; PWV=pulsewave velocity; BMI=body mass index;
WC=waist circumference; WHtR=waist-to-height ratio; WHR=waist-to-hip ratio; CI=conicity index.
doi:10.1371/journal.pone.0034699.t003
Table 4. Comparison between BMI subgroups and risk factors for CKD progression or cardiovascular events.
BMI (kg/m
2)
,25 (n=353) 25–29.9 (n=738) 30–39.9 (n=589) 40+ (n=60) p
Age(yrs) 73.59610.0 73.7968.6 71.7168.7 68.868.5 ,0.001
SBP(mmHg) 132.7620.4 134.7617.6 133.8618.2 133.1615.6 0.352
eGFR (mL/min/1.73 m
2) 52.6610.8 52.9610.4 52.1610.1 51.3610.3 0.459
UACR(mg/mmol) 0.3[0–1.8] 0.37[0–1.5] 0.33[0–1.4] 0.17[0–1.13] 0.102
Uric acid (mmol/L) 358.05686.2 379.75689.1 402.49690.5 412.826108.3 ,0.001
PWV(m/sec) 9.9962.0 10.1762.0 9.5961.9 8.8761.7 ,0.001
Data are mean6SD or median [IQR].
SBP=systolic blood pressure; eGFR=estimated glomerular filtration rate; UACR=urine albumin to creatinine ratio; PWV=pulsewave velocity; BMI=body mass index.
doi:10.1371/journal.pone.0034699.t004
Table 5. Comparison between WHR quartiles and risk factors for CKD progression or cardiovascular events.
WHR Quartiles
1
st (n=376) 2
nd (n=476) 3
rd (n=419) 4
th (n=469) p
Age(yrs) 71.43610.1 72.6468.8 73.3569.1 73.8168.2 0.001
SBP(mmHg) 132.2618.9 133.4618.6 135.7617.9 134.5617.8 0.049
eGFR (mL/min/1.73 m
2) 54.03610.3 53.95610.7 52.51610.3 49.8069.7 ,0.001
UACR(mg/mmol) 0.17[0–0.87] 0.23[0–0.9] 0.42[0–1.7] 0.77[0.07–3.4] ,0.001
Uric acid(mmol/L) 346.09684.0 369.39687.7 398.21687.5 416.99689.4 ,0.001
PWV(m/sec) 9.6862.1 9.6362.0 10.1062.0 10.1662.0 ,0.001
Data are mean6SD or median [IQR].
SBP=systolic blood pressure; eGFR=estimated glomerular filtration rate; UACR=urine albumin to creatinine ratio; PWV=pulsewave velocity; WHR=waist-to-hip ratio.
doi:10.1371/journal.pone.0034699.t005
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may be particularly important in elderly patients, in whom BMI
tends to decrease with age.
Long term follow up of this cohort will allow assessment of the
value of these anthropomorphic measurements to predict
outcomes and to identify high risk groups for possible intervention.
Further studies are required to investigate the efficacy of
interventions to reduce obesity related risks.
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